West Pharmaceutical Services Inc. (NYSE:WST) Expected to Announce Quarterly Sales of $462.78 Million

Equities research analysts forecast that West Pharmaceutical Services Inc. (NYSE:WST) will report $462.78 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for West Pharmaceutical Services’ earnings. The highest sales estimate is $466.00 million and the lowest is $457.05 million. West Pharmaceutical Services posted sales of $447.50 million during the same quarter last year, which suggests a positive year-over-year growth rate of 3.4%. The firm is scheduled to announce its next earnings report before the market opens on Thursday, July 25th.

On average, analysts expect that West Pharmaceutical Services will report full year sales of $1.81 billion for the current fiscal year, with estimates ranging from $1.80 billion to $1.82 billion. For the next financial year, analysts forecast that the company will report sales of $1.95 billion, with estimates ranging from $1.93 billion to $1.97 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow West Pharmaceutical Services.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, April 25th. The medical instruments supplier reported $0.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.08. The business had revenue of $443.50 million during the quarter, compared to analyst estimates of $431.00 million. West Pharmaceutical Services had a net margin of 12.53% and a return on equity of 16.38%. West Pharmaceutical Services’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.62 earnings per share.

A number of equities research analysts have recently weighed in on the stock. Jefferies Financial Group boosted their price objective on shares of EXACT Sciences from $100.00 to $115.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Zacks Investment Research lowered shares of Inflarx from a “buy” rating to a “hold” rating in a report on Friday, May 3rd. Finally, William Blair restated an “outperform” rating on shares of bluebird bio in a report on Tuesday, April 23rd.

In other news, VP Daniel Malone sold 4,458 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $123.03, for a total value of $548,467.74. Following the completion of the sale, the vice president now directly owns 33,478 shares in the company, valued at approximately $4,118,798.34. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 1.70% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. lifted its holdings in shares of West Pharmaceutical Services by 2.5% in the 1st quarter. BlackRock Inc. now owns 7,111,791 shares of the medical instruments supplier’s stock worth $783,720,000 after acquiring an additional 172,298 shares during the last quarter. WCM Investment Management LLC increased its stake in shares of West Pharmaceutical Services by 1.2% in the first quarter. WCM Investment Management LLC now owns 1,122,116 shares of the medical instruments supplier’s stock worth $123,658,000 after buying an additional 13,448 shares during the period. Artisan Partners Limited Partnership increased its stake in shares of West Pharmaceutical Services by 0.5% in the first quarter. Artisan Partners Limited Partnership now owns 1,111,465 shares of the medical instruments supplier’s stock worth $122,483,000 after buying an additional 5,052 shares during the period. Janus Henderson Group PLC increased its stake in shares of West Pharmaceutical Services by 5.1% in the first quarter. Janus Henderson Group PLC now owns 962,252 shares of the medical instruments supplier’s stock worth $106,040,000 after buying an additional 46,338 shares during the period. Finally, 1832 Asset Management L.P. increased its stake in shares of West Pharmaceutical Services by 0.3% in the fourth quarter. 1832 Asset Management L.P. now owns 878,420 shares of the medical instruments supplier’s stock worth $86,102,000 after buying an additional 2,400 shares during the period. Hedge funds and other institutional investors own 91.90% of the company’s stock.

Shares of WST traded down $0.06 during mid-day trading on Friday, reaching $124.43. The company’s stock had a trading volume of 188,759 shares, compared to its average volume of 252,923. The firm has a market capitalization of $9.14 billion, a PE ratio of 44.28, a PEG ratio of 3.77 and a beta of 1.30. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.13 and a current ratio of 2.88. West Pharmaceutical Services has a 52 week low of $91.75 and a 52 week high of $127.06. The stock’s fifty day moving average price is $120.60.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 7th. Stockholders of record on Wednesday, July 24th will be issued a $0.15 dividend. The ex-dividend date of this dividend is Tuesday, July 23rd. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.48%. West Pharmaceutical Services’s payout ratio is 21.35%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Featured Article: What is a front-end load?

Get a free copy of the Zacks research report on West Pharmaceutical Services (WST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.